<DOC>
	<DOC>NCT00904475</DOC>
	<brief_summary>Patients with moderate to severe chronic Low Back Pain (LBP) despite current analgesic treatment participated in a Phase IV clinical trial to evaluate the analgesic efficacy of the lidocaine patch 5% compared to placebo in treating moderate to severe chronic LBP.</brief_summary>
	<brief_title>Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>1. Were currently experiencing moderate/severe pain despite current analgesic treatment 2. Had daily moderatetosevere LBP for at least 3 months duration 3. Had a mean daily pain intensity score of &gt;6 on a 0 to 10 scale, with 0 being no pain and 10 being pain as bad as the patients have ever imagined (Question 5 of BPI) during the baseline week; patients had to complete daily diary assessments at least 5 of 7 days during the baseline week 1. Had a history of greater than one back surgery, or one back surgery within 3 months of study entry 2. Had severe spinal stenosis 3. Had chronic back pain of &gt;12 months duration with an undefined spinal diagnosis 4. Had radicular symptoms with radiation into the thigh or below (i.e., knee, calf, foot, etc.) 5. Had received an epidural steroid/local anesthetic injection within 2 weeks prior to study entry 6. Had received trigger point injections within 2 weeks prior to study entry 7. Had received Botulinum Toxin Injections for LBP within 3 months prior to study entry 8. Were taking a lidocainecontaining product that could not be discontinued while receiving study medication 9. Were taking class 1 antiarrhythmic drugs (e.g., mexiletine, tocainide) 10. Had received Lidoderm for LBP in the past</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>